Pemazyre 13.5mg (Pemigatinib Tablet) 13.5mg

Pemazyre 13.5mg tablets contain pemigatinib, a kinase inhibitor prescribed for certain cancers. This oral treatment targets fibroblast growth factor receptor alterations in adults. Suitable for metastatic or unresectable solid tumors with specific genetic markers. Short-term storage guidance may apply.

Strength

13.5mg

Manufacturer / TM Owner

Incyte Biosciences

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Pemigatinib is primarily used to treat adults with cholangiocarcinoma, a type of bile duct cancer, when the cancer has spread or cannot be removed by surgery. It is specifically indicated for patients whose tumors have a fibroblast growth factor receptor 2 fusion or other rearrangement. The medication works by blocking signals that promote cancer cell growth. It may also be used in other conditions as determined by a healthcare provider.

Side Effects

Pemazyre 13.5mg tablets may help slow the progression of certain cancers by targeting specific genetic changes in tumor cells. Patients often experience varied responses, with some noticing reduced symptoms or stabilized disease. Common effects include gastrointestinal changes such as nausea or diarrhea, which are typically temporary. Individual experiences may differ based on health status and treatment duration.

Precautions & Warnings

Store Pemazyre 13.5mg tablets at room temperature, away from moisture and direct light. Keep the medication in its original packaging until ready to use. Avoid handling crushed or broken tablets to prevent exposure. Always follow the handling instructions provided by your pharmacist or healthcare provider to ensure safety.

Avoid Interactions

Pemigatinib may interact with strong CYP3A inhibitors or inducers, which can alter its effectiveness. Grapefruit products should be avoided due to potential interactions. Discuss all current medications, including over-the-counter drugs and supplements, with your healthcare provider before starting pemigatinib. Alcohol use may increase certain side effects and should be limited.

Frequently Asked Questions

Pemigatinib is used to treat adults with certain types of bile duct cancer that has spread or cannot be removed by surgery.

Store the tablets at room temperature, away from moisture and light, in the original packaging.

Consult your healthcare provider before combining pemigatinib with other drugs, as interactions may occur.

Common effects may include nausea, diarrhea, or changes in taste, which vary by individual.

Pemazyre is a targeted therapy, not a traditional chemotherapy, as it works by blocking specific signals in cancer cells.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.